TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04697095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: : The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: : The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Blood samples
Description: : The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: : The blood sample from all groups will be taken on the day of inclusion, in the ophthalmology department. The patient will be cared for by a nurse and then taken to the collection room. A 100 ml sample will be taken (10 tubes of 10 ml). Blood samples will be labeled with the patient's identification number as part of the protocol. They will be transported to the research laboratory in order to be picked up for monocyte extraction. The purification of blood monocytes will be done. In case of excess, the samples will be destroyed at the end of the study.
Study: NCT05582746

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tri-City COVID Attitudes Study
Description: We propose a two-year study to rapidly assess (Aim 1), build and push (Aim 2), evaluate and disseminate (Aim 3) an mHealth intervention to boost COVID-19 testing and vaccine literacy, access, and uptake among women with CLSI in three cities
Study: NCT06377852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125mg
Description: Arm 1: Indicated dosing for palbociclib (125 mg orally daily on days 1-21 of 28-day cycle)
Study: NCT06700096

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ANB-002
Description: Adeno-associated viral vector carrying the FIX gene single infusion
Study: NCT05671510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gotistobart
Description: Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gotistobart
Description: Gotistobart will be administrated through IV infusion over 60 minutes, once every 21 days in assigned dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel will be administrated through IV infusion over 60 minutes, once every 21 days in 75mg/m2 dose.
Study: NCT06377852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib 600mg
Description: Arm 1: Indicated dosing of ribociclib (600 mg orally daily on days 1-21 of 28-day cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of ribociclib (400 mg or 200 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Arm 2: Titrated dosing approach with the same schedule but starting at a lower dose of palbociclib (100 mg or 75 mg) and escalating the dose if well-tolerated in combination with provider/patient choice of endocrine therapy.
Study: NCT06527404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocatinlimab
Description: SC Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SC Injection
Study: NCT05565534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-practitioner led intervention
Description: * Face-to-face or virtual consultation with NP during chemotherapy infusion with individualized recommendations/medications AND patient education through the Patient Activated Learning System (PALS).~* Weekly follow-ups from NP via phone, Zoom, or in-person (patient directed) for 12 weeks/course of chemotherapy.
Study: NCT05113966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Single-use, sterile powder to be reconstituted and further diluted with 250 milliliters (mL) of normal saline (sodium chloride solution 0.9%) or dextrose 5% in water (D5W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan-hziy
Description: 10 milligram per kilogram (mg/kg) reconstituted to a concentration of 1.1 mg/mL to 3.4 mg/mL in normal saline
Study: NCT04426968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide 2.1mg
Description: 2.1 mg/day subcutaneously (s.c.) for 24 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide 4.2mg
Description: 4.2mg/day subcutaneously (s.c.) for 24 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hepalatide 6.3mg
Description: 6.3mg/day subcutaneously (s.c.) for 24 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo 2.1mg
Description: 2.1 mg/day subcutaneously (s.c.) for 24 week
Study: NCT04987996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GR-MD-02
Description: Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive up to seventeen doses of placebo intravenously over 85 Days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.
Study: NCT05460052

Intervention type: OTHER
Intervention: Physical activity training program
Description: The physical activity training program will consist of 3 sessions per week for 6 weeks :~* 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital~* 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference.

Intervention type: OTHER
Intervention: Physical activity training program
Description: The physical activity training program will consist of 3 sessions per week for 6 weeks :~* 1 session will take place in the Sports Medicine Department of the Croix Rousse Hospital~* 2 sessions will take place remotely. They will be led by an educator in Adapted Physical Activity in live video-conference.

Intervention type: OTHER
Intervention: Weekly phone call.
Description: Patients included in the WL group will receive a weekly phone call for 6 weeks (waiting period), before starting the physical activity training program described above.

Intervention type: OTHER
Intervention: Personalized training plan.
Description: After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.

Intervention type: OTHER
Intervention: Personalized training plan.
Description: After the training program, patients of both groups will be given a personalized training plan to be followed for 4 months with regular phone call from the Adapted Physical Activity educator.
Study: NCT05252312

Intervention type: BEHAVIORAL
Intervention: Psycho-acoustic tests
Description: Listeners' cognitive and biological responses to vocal stimuli will be tested using psycho-acoustic tests. After listening to acoustic stimuli, participants will be asked to judge these stimuli on relevant evaluation criteria (e.g., how distressed does this person sound?).~These stimuli might be human voices, animal voices or synthetic voices Physiological measures will be simultaneously taken using an array of complimentary, non-invasive techniques such as the Nociception Level (NOL) Index or video pupillometry
Study: NCT05464251

Intervention type: OTHER
Intervention: Prospective chart review of subjects diagnosed with spinal epidural abscess
Description: Collection and assessment of available clinical, pathological, radiological, and socioeconomic data on subjects presenting with spinal epidural abscess. Standard of care treatment and outcomes for each group will be analyzed.

Intervention type: OTHER
Intervention: Prospective chart review of subjects diagnosed with spinal epidural abscess
Description: Collection and assessment of available clinical, pathological, radiological, and socioeconomic data on subjects presenting with spinal epidural abscess. Standard of care treatment and outcomes for each group will be analyzed.
Study: NCT05043441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and commitment therapy (ACT)
Description: Caregivers assigned to this intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 10 weeks through Zoom videoconferencing with psychoeducation materials provided.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Psychoeducation
Description: The psychoeducation control group will receive care as usual with psychoeducation materials provided.
Study: NCT05646043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Physical training consists of endurance walking and strength training. The basis for determining the number of steps per day is the baseline value of each patient. This will increase by 10-15% every week until the surgery date. The assumption of a total load increase is 120-180% compared to the baseline.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: Physical training consists of endurance walking and strength training. The basis for determining the number of steps per day is the baseline value of each patient. This will increase by 10-15% every week until the surgery date. The assumption of a total load increase is 120-180% compared to the baseline.
Study: NCT04426968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo 4.2mg
Description: 4.2 mg/day subcutaneously (s.c.) for 24 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo 6.3mg
Description: 6.3 mg/day subcutaneously (s.c.) for 24 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon
Description: 180 ug/week subcutaneously (s.c.) for 28 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon
Description: 180 ug/week subcutaneously (s.c.) for 28 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon
Description: 180 ug/week subcutaneously (s.c.) for 28 week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon
Description: 180 ug/week subcutaneously (s.c.) for 28 week
Study: NCT05564611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab 150mg
Description: A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab 150mg
Description: A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection
Study: NCT06516705

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypoglycemia education
Description: Hypoglycemia education : incleded introduction to blood glucose, hypoglycemia symptoms and treatment (15-15 rule), prevention of hypoglycemia (diet and exercise), and medication treatment.
Study: NCT06249191

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study: NCT06516705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypoglycemia education
Description: Hypoglycemia education : incleded introduction to blood glucose, hypoglycemia symptoms and treatment (15-15 rule), prevention of hypoglycemia (diet and exercise), and medication treatment.
Study: NCT06543537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Agenda-Setting Intervention
Description: A collaborative agenda-setting intervention (CASI) to promote patient-centered communication, set agendas for discussion at in-clinic visits, increase discussion of psychosocial concerns, and reduce clinician burden. The intervention is integrated into the patient portal and electronic health record. Prior to a clinic visit, the intervention elicits patients' and caregivers' preferences and concerns, then communicates this information to clinicians. Patients, caregivers, and clinicians receive communication resources, while patients and caregivers receive tailored educational materials and navigation to supportive care services.
Study: NCT06120075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB801
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB801
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB801
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB801
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB801
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB801
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB801
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB801
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered as specified in the treatment arm
Study: NCT06107023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action observation training
Description: 6 weeks, three days a week.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham action observation training
Description: 6 weeks, three days a week.
Study: NCT04284787

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT06232980

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: urological surgical intervention
Description: Anesthesia induction will be performed with propofol, and ventilation will be maintained with a laryngeal mask for urological surgical procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: urological surgical intervention
Description: Anesthesia induction will be performed with propofol, and ventilation will be maintained with a laryngeal mask for urological surgical procedures.
Study: NCT05851079

Intervention type: DIAGNOSTIC_TEST
Intervention: TCT test
Description: These tests were performed on cervical exfoliated cells.

Intervention type: DIAGNOSTIC_TEST
Intervention: TCT test
Description: These tests were performed on cervical exfoliated cells.

Intervention type: DIAGNOSTIC_TEST
Intervention: TCT test
Description: These tests were performed on cervical exfoliated cells.

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginoscopy
Description: To obtain the results of the patient's pathology report.

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginoscopy
Description: To obtain the results of the patient's pathology report.

Intervention type: DIAGNOSTIC_TEST
Intervention: High throughput HPV typing and integration detection methods
Description: This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).

Intervention type: DIAGNOSTIC_TEST
Intervention: High throughput HPV typing and integration detection methods
Description: This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).

Intervention type: DIAGNOSTIC_TEST
Intervention: High throughput HPV typing and integration detection methods
Description: This is screening for ≥ cervical intraepithelial tumors (CIN2 or CIN3).

Intervention type: DIAGNOSTIC_TEST
Intervention: Cobas HPV test
Description: To obtain HPV typing results.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cobas HPV test
Description: To obtain HPV typing results.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cobas HPV test
Description: To obtain HPV typing results.
Study: NCT04947345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Besylate
Description: Remimazolam Besylate are used as sedatives for subjects in this arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol are used as sedatives for subjects in this arm.
Study: NCT04284787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection
Study: NCT06121609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Exploring ED90 induced by remimazolam anesthesia in children of different age groups undergoing painless bidirectional endoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Exploring ED90 induced by remimazolam anesthesia in children of different age groups undergoing painless bidirectional endoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Exploring ED90 induced by remimazolam anesthesia in children of different age groups undergoing painless bidirectional endoscopy
Study: NCT04284787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT05646043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle strength training
Description: Muscle strength training will take place using exercises to strengthen the upper and lower limbs and to strengthen the trunk. There will be a set of 5 exercises in two difficulty variants. The study subjects will perform this set 7 days a week, and will repeat the assembly a total of two times. The total time of strength training is 10 min.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle strength training
Description: Muscle strength training will take place using exercises to strengthen the upper and lower limbs and to strengthen the trunk. There will be a set of 5 exercises in two difficulty variants. The study subjects will perform this set 7 days a week, and will repeat the assembly a total of two times. The total time of strength training is 10 min.
Study: NCT04284787

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA scan
Study: NCT04854044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt/ERK Inhibitor ONC201
Description: Given orally

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT05775159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Volrustomig
Description: CTLA-4/Anti-PD-1 Bispecific Antibody
Study: NCT05933356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: playing exergames
Description: will be provided with the individual brain training exergames three times a week and 30 minutes each time